These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. O'Brien ME; Ciuleanu TE; Tsekov H; Shparyk Y; Cuceviá B; Juhasz G; Thatcher N; Ross GA; Dane GC; Crofts T J Clin Oncol; 2006 Dec; 24(34):5441-7. PubMed ID: 17135646 [TBL] [Abstract][Full Text] [Related]
5. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. Eckardt JR; von Pawel J; Pujol JL; Papai Z; Quoix E; Ardizzoni A; Poulin R; Preston AJ; Dane G; Ross G J Clin Oncol; 2007 May; 25(15):2086-92. PubMed ID: 17513814 [TBL] [Abstract][Full Text] [Related]
6. New advances in the second-line treatment of small cell lung cancer. Hurwitz JL; McCoy F; Scullin P; Fennell DA Oncologist; 2009 Oct; 14(10):986-94. PubMed ID: 19819917 [TBL] [Abstract][Full Text] [Related]
7. Typhlitis during second-line chemotherapy with pemetrexed in non-small cell lung cancer (NSCLC): A case report. Tiseo M; Gelsomino F; Bartolotti M; Barili MP; Ardizzoni A Lung Cancer; 2009 Aug; 65(2):251-3. PubMed ID: 19346026 [TBL] [Abstract][Full Text] [Related]
8. A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer. Shah C; Ready N; Perry M; Kirshner J; Gajra A; Neuman N; Garziano S Lung Cancer; 2007 Jul; 57(1):84-8. PubMed ID: 17399850 [TBL] [Abstract][Full Text] [Related]
9. Talactoferrin alpha receives fast-track designation for the treatment of non-small cell lung cancer. McBride D ONS Connect; 2007 Jan; 22(1):14. PubMed ID: 17393636 [No Abstract] [Full Text] [Related]
10. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. Di Maio M; Chiodini P; Georgoulias V; Hatzidaki D; Takeda K; Wachters FM; Gebbia V; Smit EF; Morabito A; Gallo C; Perrone F; Gridelli C J Clin Oncol; 2009 Apr; 27(11):1836-43. PubMed ID: 19273711 [TBL] [Abstract][Full Text] [Related]
11. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Jiang J; Liang X; Zhou X; Huang R; Chu Z Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133 [TBL] [Abstract][Full Text] [Related]
12. [Stage IV non-small cell lung cancer. What is the best treatment for relapse?]. Sculier JP Rev Mal Respir; 2006 Nov; 23(5 Pt 3):16S78-16S83. PubMed ID: 17268341 [TBL] [Abstract][Full Text] [Related]
13. A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer. Shibayama T; Hotta K; Takigawa N; Tada A; Ueoka H; Harita S; Kiura K; Tabata M; Segawa Y; Nogami N; Kuyama S; Shinkai T; Tanimoto M Lung Cancer; 2006 Aug; 53(2):189-95. PubMed ID: 16806573 [TBL] [Abstract][Full Text] [Related]
14. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. Burris HA Oncogene; 2009 Aug; 28 Suppl 1():S4-13. PubMed ID: 19680296 [TBL] [Abstract][Full Text] [Related]
17. First-line chemotherapy for non-small-cell lung cancer: is there a superior regimen based on histology? Einhorn LH J Clin Oncol; 2008 Jul; 26(21):3485-6. PubMed ID: 18506022 [No Abstract] [Full Text] [Related]
19. Recent advances with topotecan in the treatment of lung cancer. O'Brien M; Eckardt J; Ramlau R Oncologist; 2007 Oct; 12(10):1194-204. PubMed ID: 17962613 [TBL] [Abstract][Full Text] [Related]
20. Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy. Bearz A; Serraino D; Fratino L; Berretta M; Tirelli U Cancer; 2007 Dec; 110(11):2593-4; author reply 2594. PubMed ID: 17960771 [No Abstract] [Full Text] [Related] [Next] [New Search]